LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 1.18 USD -7.09% Market Closed
Market Cap: 31m USD

LAVA Therapeutics NV
Other Non-Cash Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

LAVA Therapeutics NV
Other Non-Cash Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Non-Cash Items CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Other Non-Cash Items
$4.3m
CAGR 3-Years
64%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Other Non-Cash Items
$11.1m
CAGR 3-Years
464%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
ProQR Therapeutics NV
NASDAQ:PRQR
Other Non-Cash Items
-€805k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
14%
Uniqure NV
NASDAQ:QURE
Other Non-Cash Items
$45.7m
CAGR 3-Years
N/A
CAGR 5-Years
17%
CAGR 10-Years
16%
argenx SE
XBRU:ARGX
Other Non-Cash Items
$241.3m
CAGR 3-Years
37%
CAGR 5-Years
41%
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Other Non-Cash Items
$3m
CAGR 3-Years
N/A
CAGR 5-Years
-13%
CAGR 10-Years
N/A

LAVA Therapeutics NV
Glance View

Market Cap
31m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
1.96 USD
Undervaluation 40%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Other Non-Cash Items?
Other Non-Cash Items
4.3m USD

Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Other Non-Cash Items amounts to 4.3m USD.

What is LAVA Therapeutics NV's Other Non-Cash Items growth rate?
Other Non-Cash Items CAGR 3Y
64%

Over the last year, the Other Non-Cash Items growth was 427%. The average annual Other Non-Cash Items growth rates for LAVA Therapeutics NV have been 64% over the past three years .

Back to Top